In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology

Set Alert for Oncology

Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio

Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.

BioPharmaceutical Growth Business Strategies

Innovation In Oncology: An Infographic

Oncology innovation: lots of drugs, lots of trials, sometimes not enough patients. And styles of innovation depend on whether a company has a big franchise to defend or would like one. In Vivo presents current data on sales, pipelines, trials and fails. (Free article.)

BioPharmaceutical Cancer Research and Development Strategies
Advertisement

CAR-T Commercialization Strategies: Views From Novartis And Kite

At recent industry events, Novartis and Kite Pharma highlighted opportunities and addressed challenges they face as they prepare to commercialize their CAR-T therapies. A report from Datamonitor Healthcare.

Regenerative Medicine Commercial Cancer

ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.

BioPharmaceutical Deals ImmunoOncology

Oncology Disruption Demands Strategic Transformation

The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this new landscape, biopharma companies must transform their portfolios and partnerships, and shift toward more dynamic business and operating models and decision-making processes.

BioPharmaceutical Business Strategies Cancer

Inside Bayer Oncology: An Interview With Robert LaCaze

Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.

Business Strategies Deals BioPharmaceutical

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?

With 70 clinical trials now underway on a “next generation” of more precisely targeted antibody drug conjugates, In Vivo profiles Ambrx and Sutro Biopharma, two smaller biotechs with promising technologies and powerful partners that augment their strong science with disease awareness, deep commercial networks and global geographic reach.

BioPharmaceutical Cancer Innovation

With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Business Strategies Cancer BioPharmaceutical

Free And Open: The Next Wave In Clinical Trial Data?

Transparency is an issue that continues to pose reputational challenges for biopharma. A key flashpoint is the disclosure – under open access rules – of clinical trial data in a climate of mounting therapeutic competition. Still, some industry players are pushing the boundaries around open access. Project Data Sphere, a non-profit group backed by the CEO Roundtable on Cancer, is taking advantage of new IT platforms and the rich target potential in discovery science to press for a larger industry consensus around new ways to release high-value data embedded in years of trials, all for the benefit of cancer patients.

Clinical Trials Platform Technologies BioPharmaceutical

When Two Worlds Collide – BTG Brings Interventional Oncology And Immunotherapy Together

BTG's range of interventional oncology technologies puts it in an enviable position in R&D initiatives that require a holistic view across cancer and the best-targeted therapies. The UK-listed company will now take this to another level following an agreement with the Society of Interventional Oncology to explore the role of minimally invasive therapies in immuno-oncology.

ImmunoOncology Research and Development Strategies Cancer

Finding The Right Path To Category Leadership In Oncology

Oncology drug development is undergoing rapid shifts. Bain research shows companies that seek to lead in specific vertical categories outperform rivals that invest across a broad spectrum of cancer targets.

Business Strategies Growth Cancer

Schilsky On ASCO 2017: The “You” Factor In Cancer Care

ASCO’s 2017 annual meeting is expanding its focus on patient wellness beyond the clinic, with new research highlighting prevention, alternative treatments post-surgery, psycho-social factors and other issues reflecting the concerns of a growing new constituency of cancer survivors. In Vivo discusses this year’s agenda with ASCO’s CMO, Richard Schilsky.

BioPharmaceutical Cancer Market Access

CAR-T Cancer Drugs Front And Center At ARM Investor Day

Labeling, logistics and other issues were on the table as industry experts discussed the potential upcoming launches of CAR-T therapies in the US. Datamonitor Healthcare reported live from the ARM conference.

Regenerative Medicine Commercial Cancer

Combinations Continue To Drive Immuno-Oncology Deal-Making

The pursuit by the industry to find novel combinations that can address more patients and more tumor types has driven overall immuno-oncology deal activity by big pharma and mid pharma companies between 2012 and 2016.

Deals ImmunoOncology Cancer

More on Oncology from Scrip, Pink Sheet & Medtech Insight.

Dual Approval For Verzenio Under International Review Scheme

The joint review by Australia and Canada of the metastatic breast cancer drug, Verzenio, helped regulators in both jurisdictions achieve efficiencies.

Approvals Market Access

Kiadis Buying CytoSen Will Combine Natural Killer And T-Cell Immunotherapies

An all-stock transaction will see Europe’s Kiadis and US’s CytoSen bring together complementary approaches to improving stem cell transplants and cancer immunotherapy.

 

M & A ImmunoOncology

Asia Begins To See Impact From Roche 'De-Siloing'

As part of a global strategy first unveiled last year, Roche is taking concrete steps to restructure its pharma operations in Asia, including the substantial downsizing of a Singapore office.

Business Strategies Asia Pacific

Guardant360 Lung-Cancer Assay Beats Tissue Genotyping In NILE

New trial results show Guardant Health's Guardant360 largest cell-free DNA assay rapidly identifies biomarkers for metastatic non-small cell lung cancer associated with specific therapies at least as accurately as standard-of-care tissue genotyping.

Clinical Trials Cancer

Global Device Approvals Snapshot: April 9-15, 2019

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved Qiagen's therascreen FGFR RGQ RT-PCR companion diagnostic for Janssen's new drug to treat specific types of urothelial cancer and Intact Vascular's Tack device to treat dissections of the above-the-knee peripheral arteries following angioplasty.

Research & Development Approvals

FDA Approves Qiagen’s Therascreen Urothelial Cancer Companion Diagnostic

The Therascreen FGFR kit helps identify urothelial tumors with alterations to the fibroblast growth factor receptor 3 gene that indicate the cancer will respond to Janssen’s new drug Balversa.

Research & Development Approvals
UsernamePublicRestriction

Register